{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:20:46Z","timestamp":1789852846570,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00296-017-3861-8","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T09:32:09Z","timestamp":1509010329000},"page":"161-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab"],"prefix":"10.1007","volume":"38","author":[{"given":"Anastasia","family":"Skalkou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia-Magdalini","family":"Manoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Sachinidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Ntouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Petidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Pagkopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Vakirlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Pyrpasopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-1642","authenticated-orcid":false,"given":"Theodoros","family":"Dimitroulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"3861_CR1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","volume":"27","author":"C Monaco","year":"2015","unstructured":"Monaco C, Nanchahal J, Taylor P, Feldmann M (2015) Anti-TNF therapy: past, present and future. Int Immunol 27:55\u201362","journal-title":"Int Immunol"},{"key":"3861_CR2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/annrheumdis-2016-210239","volume":"76","author":"T Olofsson","year":"2017","unstructured":"Olofsson T, Petersson IF, Eriksson JK, ARTIS Study Group et al (2017) Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work? Ann Rheum Dis 76:1245\u20131252","journal-title":"Ann Rheum Dis"},{"key":"3861_CR3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","volume":"76","author":"AS Low","year":"2016","unstructured":"Low AS, Symmons DP, Lunt M et al (2016) British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) and the BSRBR Control Centre Consortium. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 76:654\u2013660","journal-title":"Ann Rheum Dis"},{"key":"3861_CR4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","volume":"7","author":"R Denadai","year":"2013","unstructured":"Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R (2013) Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis 7:517\u2013524","journal-title":"J Crohns Colitis"},{"key":"3861_CR5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/RHU.0b013e3182a702e8","volume":"19","author":"K Nguyen","year":"2013","unstructured":"Nguyen K, Vleugels RA, Velez NF, Merola JF, Qureshi AA (2013) Psoriasiform reactions to anti-tumor necrosis factor \u03b1 therapy. J Clin Rheumatol 19:377\u2013381","journal-title":"J Clin Rheumatol"},{"key":"3861_CR6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417","journal-title":"Rheumatol Int"},{"key":"3861_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-0996-1","author":"W L\u00f6ffler","year":"2017","unstructured":"L\u00f6ffler W, Lohse P, Weihmayr T, Widenmayer W (2017) Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome: differential diagnosis of septic arthritis by regular detection of exceedingly high synovial cell counts. Infection. doi: 10.1007\/s15010-017-0996-1","journal-title":"Infection"},{"key":"3861_CR8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2340\/00015555-2008","volume":"95","author":"Patel Fl","year":"2015","unstructured":"Fl Patel, Fitzmaurice S, Duong C et al (2015) Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol 95:525\u2013531","journal-title":"Acta Derm Venereol"},{"key":"3861_CR9","first-page":"378","volume":"58","author":"R Saigal","year":"2010","unstructured":"Saigal R, Singh Y, Mittal M, Kansal A, Maharia HR (2010) Pyoderma gangrenosum. J Assoc Physicians India 58:378\u2013383","journal-title":"J Assoc Physicians India"},{"issue":"2","key":"3861_CR10","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","volume":"15","author":"\u00c9 Toussirot","year":"2016","unstructured":"Toussirot \u00c9, Aubin F (2016) Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 15(2):e000239","journal-title":"RMD Open"},{"key":"3861_CR11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A et al (2006) Infliximab for treatment of pyoderma gangrenosum: a randomized, double blind placebo controlled trial. Gut 55:505\u2013509","journal-title":"Gut"},{"key":"3861_CR12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1684\/ejd.2015.2526","volume":"25","author":"M Vestita","year":"2015","unstructured":"Vestita M, Guida S, Mazzoccoli S, Loconsole F, Foti C (2015) Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab. Eur J Dermatol 25:272\u2013273","journal-title":"Eur J Dermatol"},{"key":"3861_CR13","first-page":"447","volume":"11","author":"L Kowalzick","year":"2013","unstructured":"Kowalzick L, Bertolini J, Baumann C et al (2013) Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges 11:447\u2013449","journal-title":"J Dtsch Dermatol Ges"},{"key":"3861_CR14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2340\/00015555-0777","volume":"90","author":"AM Brunasso","year":"2010","unstructured":"Brunasso AM, Laimer M (2010) Massone C (2010) Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Derm Venereol 90:183\u2013185","journal-title":"Acta Derm Venereol"},{"key":"3861_CR15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3315\/jdcr.2009.1027","volume":"3","author":"N Jaimes-L\u00f3pez","year":"2009","unstructured":"Jaimes-L\u00f3pez N, Molina V, Arroyave JE et al (2009) Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Rep 3:20\u201323","journal-title":"J Dermatol Case Rep"},{"key":"3861_CR16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/archderm.144.6.817","volume":"144","author":"M Stichenwirth","year":"2008","unstructured":"Stichenwirth M, Riedl E, Pehamberger H, Tappeiner G (2008) Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? Arch Dermatol 144:817\u2013818","journal-title":"Arch Dermatol"},{"key":"3861_CR17","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s10067-007-0733-8","volume":"26","author":"K Vandevyvere","year":"2007","unstructured":"Vandevyvere K, Luyten FP, Verschueren P (2007) Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in patient with rheumatoid arthritis. Clin Rheumatol 26:2205\u20132206","journal-title":"Clin Rheumatol"},{"key":"3861_CR18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/0961203313517153","volume":"23","author":"AM Brunasso","year":"2014","unstructured":"Brunasso AM, Aberer W, Massone C (2014) Subacute lupus erythematosus duringtreatment with golimumab for seronegative rheumatoid arthritis. Lupus 23:201\u2013203","journal-title":"Lupus"},{"key":"3861_CR19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2008.10.060","volume":"61","author":"AE Moustou","year":"2009","unstructured":"Moustou AE, Matekovits A, Dessinioti C et al (2009) Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 61:486\u2013504","journal-title":"J Am Acad Dermatol"},{"key":"3861_CR20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjd.15193","volume":"177","author":"BC Wu","year":"2017","unstructured":"Wu BC, Patel ED, Ortega-Loayza AG et al (2017) Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol 177:72\u201383","journal-title":"Br J Dermatol"},{"key":"3861_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0308-7","author":"JY Wang","year":"2017","unstructured":"Wang JY, French LE, Shear NH, Amiri A, Alavi A (2017) Drug-induced pyoderma gangrenosum: a review. Am J Clin Dermatol. doi: 10.1007\/s40257-017-0308-7","journal-title":"Am J Clin Dermatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-017-3861-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3861-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3861-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T14:20:20Z","timestamp":1603203620000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-017-3861-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3861"],"URL":"https:\/\/doi.org\/10.1007\/s00296-017-3861-8","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]}}}